BioSpace News Archive

CURE Pharmaceutical Holding Corp. announced today that it has signed a partnership agreement with Biopharmaceutical Research Company , (BRC), an active Drug Enforcement Administration (DEA) license holder, to produce federally-compliant cannabis-based medical products.

Ambrx Announces Formation and Members of Scientific Advisory Board.

CBMG Holdings (or the “Company”), a biopharmaceutical company developing innovative cellular immunotherapies for the treatment of cancer, today announced updated clinical data for C-CAR039, a novel CD19/CD20 bi-specific CAR-T cell product in relapsed or refractory (r/r) B-cell non-Hodgkin lymphoma (B-NHL)

Medexus Pharmaceuticals Inc. announced that it has expanded its medical affairs team in preparation for the planned launch of treosulfan, a bifunctional alkylating agent, in the United States.

Oxurion NV announces that it has received Institutional Review Board approval to initiate a Phase 2 clinical study of THR-687 in patients with Diabetic Macular Edema.

Pfizer Inc. and BioNTech SE announced plans to provide the U.S. government at a not-for-profit price 500 million doses of the companies’ COVID-19 vaccine, 200 million doses in 2021 and 300 million doses in the first half of 2022, to further support the multilateral efforts to address the surge of infection in many parts of the world and to help end the pandemic.

Sensorion announces the appointment of Nora Yang, Ph.D., a leader in gene therapy and rare diseases with extensive leadership experience in industry, academia, and government, as Chief Scientific Officer.

The most recent ratings from the Centers for Medicare & Medicaid Services show Satellite Healthcare is leading the industry, having received the highest percentage of Patient Experience 4 and 5 star rated centers as compared to all other top ranked dialysis providers in the United States.

Starton Therapeutics Inc. announced that it has been selected to deliver a company presentation at 2021 BIO Digital, the premier biotech event.

Oyster Point Pharma, Inc. announced a newly formed research collaboration with Adaptive Phage Therapeutics to leverage APT’s PhageBank™ technology for the development of potential treatments for multiple ophthalmic diseases.